Enterprise information has been authenticated 
TINAVI has served orthopedic robotic surgery from 2005 in China, and committed to providing orthopedic surgical robots, including robotic assisted spinal surgery, robotic assisted joint replacement surgery and robotic assisted trauma surgery.
TINAVI Medical Technologies Co., Ltd. (Stock Code: 688277; hereinafter referred to as "TINAVI") is a high-tech enterprise focusing on the independent innovation, large-scale production, professional marketing and high-quality clinical application of orthopedic surgical robots and related technologies. It is also the first enterprise in China and the fifth enterprise in the world to obtain a medical robot registration license. In 2020, TINAVI was successfully listed on the STAR Market.
As a pioneer of medical robots in China, TINAVI has obtained more than 300 patents.
TINAVi won the Second Prize of the 2015 National Science and Technology Progress Award and hosted a postdoctoral research workstation.
Member unit of the National Robot Standardization Group of China;
Supporting unit of "National and Local Joint Engineering Research Center of Medical Robot"
China Medical Equipment Association governing unit
Chinese Biomedical Engineering Society Medical robot engineering and clinical application branch vice chairman unit
Member enterprise of the China Robotic TOP10 Summit
Beijing biomedicine Industry Leapfrog Development Project (G20 Project) innovation leading enterprises
TiRobot, the core product of TINAVI, innovates the orthopedic surgical robot in the world. It covers multiple indications with one system, including spinal surgeries for all segments(cervical, thoracic, lumbar and sacral vertebrae), trauma surgeries(pelvis, acetabulum, extremities and other parts) and joint replacement surgeries. By the end of the second quarter of 2026, the clinical application of the TiRobot orthopedic robots has covered more than 200 medical institutions in 31 provinces, autonomous regions and directly-administered municipalities, and the number of cases has exceeded 180,000.
